KALA BIO files legal opinion for securities offering
KALA BIO, Inc. reports that on July 22, 2026 it filed a prospectus supplement pursuant to Rule 424(b) under the Securities Act of 1933, relating to an offering of securities under its effective Registration Statement on Form S-3 (File No. 333-295667).
Rhea-AI Filing Summary
KALA BIO, Inc. reports that on July 22, 2026 it filed a prospectus supplement pursuant to Rule 424(b) under the Securities Act of 1933, relating to an offering of securities under its effective Registration Statement on Form S-3 (File No. 333-295667).
The company is providing a legal opinion on the validity of the securities being offered, furnished as Exhibit 5.1 from Haynes and Boone, LLP, together with a related consent in Exhibit 23.1 and an Inline XBRL cover page data file.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Prospectus supplement date: July 22, 2026
Registration Statement File Number: 333-295667
Common stock par value: $0.001 per share
3 metrics
Prospectus supplement date
July 22, 2026
Date KALA BIO filed the Rule 424(b) prospectus supplement
Registration Statement File Number
333-295667
Form S-3 registration statement referenced for the offering of securities
Common stock par value
$0.001 per share
Par value of KALA BIO common stock listed on The Nasdaq Capital Market
Key Terms
prospectus supplement, Registration Statement on Form S-3, Rule 424(b), Inline XBRL
4 terms
prospectus supplement regulatory
"filed a prospectus supplement pursuant to Rule 424(b)"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Registration Statement on Form S-3 regulatory
"offering of securities pursuant to the Company’s effective Registration Statement on Form S-3"
A registration statement on Form S‑3 is a short, standardized filing a qualified public company uses to register new securities with regulators so they can be sold to investors; think of it as a pre-approved, reusable permission slip that speeds up future offerings. It matters to investors because it lets the company raise money more quickly and cheaply — which can fund growth or pay debt — but may also lead to share dilution or change in ownership, so it affects value and liquidity.
Rule 424(b) regulatory
"filed a prospectus supplement pursuant to Rule 424(b) under the Securities Act"
Rule 424(b) is a U.S. Securities and Exchange Commission requirement that companies file the exact prospectus or prospectus supplement they use to sell securities after a registration statement becomes effective. Think of it as the official posting of the final sales brochure so investors can see the precise terms, risks and use of proceeds; it matters because it ensures transparency, helps investors compare offerings and confirms the issuer complied with disclosure rules.
Inline XBRL technical
"Cover Page Interactive Data File (embedded within the Inline XBRL document)"
Inline XBRL is a file format for financial filings that embeds machine-readable data tags directly inside the human-readable report, so the same document can be read by people and parsed by software. For investors it makes extracting, comparing and verifying financial numbers faster and more reliable—like a grocery list where each item also has a barcode—reducing manual errors and speeding up analysis.
FAQ
What action did KALA (KALA) take on July 22, 2026?
On July 22, 2026, KALA BIO, Inc. filed a prospectus supplement under Rule 424(b) tied to its effective Form S-3 Registration Statement and provided a legal opinion on the validity of the securities being offered as Exhibit 5.1.
What is the purpose of KALA BIO's prospectus supplement under Form S-3 (KALA)?
The prospectus supplement supports an offering of securities pursuant to KALA BIO’s effective Registration Statement on Form S-3 (File No. 333-295667), and is accompanied by a legal opinion confirming the validity of those securities.
Who provided the legal opinion for KALA BIO (KALA) and how is it referenced?
The legal opinion on the validity of the securities offered under the prospectus supplement was provided by Haynes and Boone, LLP. It is included as Exhibit 5.1, with a related consent contained in Exhibit 23.1.
How does this filing relate to KALA BIO's existing Form S-3 registration (KALA)?
The action relates to KALA BIO’s effective Registration Statement on Form S-3 (File No. 333-295667). The company’s prospectus supplement and accompanying legal opinion address securities offered under that previously declared-effective shelf registration.
Which KALA BIO securities are listed on The Nasdaq Capital Market (KALA)?
KALA BIO lists its Common Stock, $0.001 par value per share, on The Nasdaq Capital Market under the trading symbol KALA, as indicated in the table of securities registered under Section 12(b).
AI-generated analysis. How Rhea-AI works. Not financial advice.
